The Duke Funding Alert newsletter, published every Monday, provides information on all new and updated grants and fellowships added to the database during the prior week. This listserv is restricted to members of the Duke community.
Congressionally Directed Medical Research Programs -- Prostate Cancer Research Program -- Dr. Barbara Terry-Koroma Health Disparity Research Award
The FY21 PCRP Health Disparity Research Award supports promising research ideas that have high potential to make a significant impact in eliminating disparities in prostate cancer incidence, morbidity, mortality, and survivorship. Applications for this award are encouraged to be relevant to one or more of the FY21 PCRP Health Disparity Research Award Focus Areas and must explicitly state how the proposed research is related to the selected focus area(s). If the proposed project does not address one of the FY21 PCRP Health Disparity Research Award Focus Areas, the application must provide a description to justify how the project will nevertheless address a critical disparity-related need within the context of the FY21 PCRP Overarching Challenges. Applications are encouraged from a spectrum of disciplines, including but not limited to basic science, engineering, bioinformatics, population science, psychooncology, translational research, health care services.
• Required Pre-Application Deadline: July 15, 2021
• Application Submission Deadline: July 29, 2021
Areas of Interest
The Mission of the FY21 PCRP is to fund research that will lead to the elimination of death from prostate cancer and enhance the well-being of Service Members, Veterans, and all the men and their families who are experiencing the impact of the disease. Within this context, the PCRP is interested in supporting research that addresses specific gaps in prostate cancer research and clinical care; therefore, applications are required to address one or more of the following FY21 PCRP Overarching Challenges:
• Improve quality of life to enhance outcomes and overall health and wellness for those impacted by prostate cancer.
Applications should aim to understand the impact of prostate cancer on quality of life for the cancer survivor, their family, caregivers, and their community with the goal of improving and enhancing quality of life and overall health and wellness. Studies should consider both shortand long-term quality of life outcomes. Areas of particular interest include: o The mental and emotional health of patients and their families/caregivers o Impact of quality of life considerations on decision-making after diagnosis and/or treatment o Identification of vulnerable groups of men and their families at great risk of quality of life detriments o Translation of factors or interventions that improve quality of life outcomes and overall health and wellness
• Develop treatments that improve outcomes for men with lethal prostate cancer
Applications must be directly related to prostate cancer with a high risk of death, including high-risk, very high-risk, and metastatic prostate cancer. Applications should not focus on active surveillance, low-risk and intermediate-risk prostate cancer and/or biochemical recurrence. Refer to the National Comprehensive Cancer Network guidelines for risk assessment definitions (https://www.nccn.org/patients/guidelines/content/PDF/prostateadvanced-pa...).
• Advance Health Equity and Reduce Disparities in Prostate Cancer
Applications must be directly relevant to the better understanding and/or reduction of inequities and disparities that impact a person, their family, or their caregiver's ability to prevent, detect, manage, and survive prostate cancer. Inequities may arise from socioeconomic status, race or ethnicity, geography, environment, lifestyle, sexual and/or gender identification, access to care (in rural or urban settings), or other factors. Health inequities may include physical, mental, or emotional health differences, as well as social and financial differences experienced primarily in high-risk or underserved prostate cancer patients. High-risk populations include, but are not limited to, people of African descent (including Caribbean), genetically predisposed populations, Service Members, and Veterans. Underserved populations include, but are not limited to, men with limited access to clinical care and resources (in rural or urban settings), and sexual and/or gender minorities.
• Define the biology of lethal prostate cancer to reduce death
Applications must be directly related to prostate cancer with a high risk of death, including high-risk, very high-risk, and metastatic prostate cancer. Applications should not focus on active surveillance, low-risk and intermediate-risk prostate cancer, and/or biochemical recurrence. Refer to the National Comprehensive Cancer Network guidelines for risk assessment definitions (https://www.nccn.org/patients/guidelines/content/PDF/prostateadvanced-pa...).
The PCRP is interested in research that addresses all different aspects that contribute to health disparity in prostate cancer. The Focus Areas outlined below broadly describe the primary areas that may contribute to disparities in prostate cancer incidence, morbidity, mortality, and survivorship:
• Biological contributors, such as genetic and genomic differences, that can be associated with disparate outcomes in patient populations.
• Environmental factors that may cause endogenous changes, such as environmental exposures, dietary factors, lifestyle factors, and other external factors that may contribute to prostate cancer disparities in specific populations.
• Social and cultural factors that may influence decision-making of patients, their family, or caregiver as it relates to the screening and treatment of prostate cancer, such as the role of social/support networks, community influence, cultural or religious practices, and psychological health.
• Access to health care, which may stem from geographic location, socioeconomic status, or other factors.
Each investigator may be named on only one FY20 PCRP Health Disparity Research Award application as PI.
Although a PI may be eligible for both the Established Investigator and New Investigator categories, only one category may be chosen; the choice of application category is at the applicant’s discretion.
- The PI must be an independent investigator at or above the level of Assistant Professor (or equivalent).
New Investigator: By the application submission deadline, the PI must have:
○ The freedom to pursue independent research goals without formal mentorship; ○ Not previously received a PCRP Health Disparity Research Award and/or Idea Development Award;
○ The PI must be an independent, early-career investigator within 10 years after completion of his/her terminal degree by the time of the application submission deadline (excluding time spent in residency or on family medical leave). Time spent as a postdoctoral fellow is not excluded. Lapses in research time or appointments as denoted in the biographical sketch may be articulated in the application.
○ New Investigators working under another investigator are eligible to apply for this award provided they can demonstrate that they have the freedom to pursue independent research goals without formal mentorship. Graduate students and junior postdoctoral fellows (i.e., fellows with less than 3 years of postdoctoral training by the application submission deadline) are not eligible to apply as a New Investigator.
The anticipated direct costs budgeted for the entire period of performance for an FY20 PCRP Health Disparity Research Award will not exceed $750,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.